





Provider Help Desk 1.866.399.0928

#### Request for Prior Authorization HEPATITIS C TREATMENTS

(PLEASE PRINT – ACCURACY IS IMPORTANT) DOB IA Medicaid Member ID # Patient name Patient address Patient phone Provider NPI Prescriber name Phone Prescriber address Fax Address Pharmacy name Phone Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned. NDC Pharmacy NPI Pharmacy fax Prior authorization (PA) is required for hepatitis C treatments. Requests for non-preferred agents may be considered when documented evidence is provided that the use of the preferred agents would be medically contraindicated.

Payment will be considered under the following conditions: 1) Patient has a diagnosis of chronic hepatitis C; and 2) Patient's age and/or weight is within the FDA labeled age and/or weight; and 3) Patient has had testing for hepatitis C virus (HCV) genotype; and 4) Patient has an active HCV infection verified by a detectable viral load within 12 months of starting treatment; and 5) Patient has been tested for hepatitis B (HBV) prior to initiating treatment of HCV and individuals with active HBV infection are treated (either at same time as HCV therapy or before HCV therapy is started); and 6) Patient's prior treatment history is provided (treatment naïve or treatment experienced); and 7) If patient has a history of non-compliance, documentation that steps have been taken to correct or address the causes of noncompliance are provided; and 8) Patient has abstained from the use of illicit drugs and alcohol for a minimum of three (3) months as evidenced by a negative urine confirmation test; and 9) HCV treatment is prescribed by or in consultation with a digestive disease, liver disease, or infectious disease provider practice; and 10) For patients on a regimen containing ribavirin, documentation of the following on the PA form: a) Patient is not a pregnant female or a male with a pregnant female partner; and b) Women of childbearing potential and their male partners must use two forms of effective contraception during treatment and for at least 6 months after treatment has concluded; and c) Monthly pregnancy tests will be performed during treatment; and 11) Prescriber has reviewed the patient's current medication list and acknowledged that there are no significant drug interactions with the HCV medication; and 12) Documentation is provided for patients who are ineligible to receive ribavirin. 13) Non-FDA approved or non-compendia indicated combination therapy regimens will not be approved. 14) Patient does not have limited life expectancy (less than 12 months) due to non-liver-related comorbid conditions. 15) If patient is recently eligible for lowa Medicaid, and has been started and stabilized on therapy while covered under a different plan, documentation of how long the patient has been on medication will be required. Patient will be eligible for the remainder of therapy needed, based on established length of therapy for the particular treatment (defined below). 16) Lost or stolen medication replacement requests will not be authorized. 17) The 72-hour emergency supply rule does not apply to hepatitis C treatments. 18) Only one treatment attempt will be allowed per calendar year, regardless of compliance.

Preferred: Mavyret	Non-Preferred:	☐ Epclusa	☐ ledipasvir/sofosbuvir
☐ sofosbuvir/velpatasvir		☐ Harvoni	☐ Sovaldi
Harvoni 45mg-200mg (3-11 y/o & < 35kg)			☐ Vosevi
☐ Sovaldi 200mg (3-11 y/o & < 35kg)			☐ Zepatier

Rev. 10/20 Page 1 of 9





Provider Help Desk 1.866.399.0928

#### Request for Prior Authorization HEPATITIS C TREATMENTS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

#### Instructions for completing the Hepatitis C Treatments PA form:

Section 1 of the PA form lists the various regimens and clinical situations for which hepatitis C treatments will be considered medically necessary according to Iowa Medicaid PA criteria. Section 2 includes additional supporting documentation that is required on the PA form.

- Check ONE box in Section 1 Treatment Regimen.
- Review and complete each numbered item in Section 2 Supporting Documentation.
- Attach lab results, chart notes, and other documentation, sign, and fax the completed form to (800) 574-2515.

#### <u>SECTION 1 – TREATMENT REGIMEN</u>

Check ONE box below to indicate the requested treatment regimen based on the patient's genotype, treatment history, and extent of liver disease.

Genotype 1 (Note: the subtype is listed if there are differences in the recommended treatments)				
Treatment naïve, no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
sofosbuvir/velpatasvir one tablet daily for 12 weeks				
Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY), HIV negative				
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
sofosbuvir/velpatasvir one tablet daily for 12 weeks				
Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY), HIV positive				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
Treatment experienced (PEG-IFN/RBV ONLY), no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
Treatment experienced (PEG-IFN/RBV ONLY), compensated cirrhosis (Child-Pugh A ONLY)				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
Treatment experienced (PEG-IFN/RBV + NS3/4A protease inhibitor (telaprevir, boceprevir, simeprevir), no prior NS5A,				
no prior sofosbuvir), no or compensated cirrhosis (Child-Pugh A ONLY)				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
Treatment experienced (Non-NS5A inhibitor, sofosbuvir containing regimen), no or compensated cirrhosis (Child-Pugh A ONLY)				
,				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Sub-type 1b ONLY: sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment experienced, any NS5A inhibitor but NO NS3/4A protease inhibitor (prior therapy ONLY with				
ledipasvir+sofosbuvir or sofosbuvir +velpatasvir), no or compensated cirrhosis (Child-Pugh A ONLY)				
☐ Mavyret 100/40 mg, three (3) tablets daily for 16 weeks				
☐ Vosevi 400/100/100 mg, one tablet daily for 12 weeks				
Vosevi 400/100/100 mg, one tablet dally for 12 weeks				
Treatment experienced (prior treatment with any NS5A inhibitor (ledipasvir (Harvoni), velpatasvir (Epclusa/Vosevi),				
elbasvir (Zepatier), dasabuvir (Viekira), , including those given with a NS3/4A protease inhibitor, but NOT including				
glecaprevir/pibrentasvir (Mavyret) or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures), no cirrhosis or compensated				
cirrhosis (Child-Pugh A ONLY)				
☐ Vosevi 400/100/100 mg, one tablet daily for 12 weeks				
Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, no cirrhosis				
☐ Vosevi 400/100/100 mg, one tablet daily for 12 weeks				
Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, compensated cirrhosis (Child-Pugh A ONLY)				
☐ Vosevi 400/100/100 mg, one tablet daily plus weight-based ribavirin for 12 weeks				
Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, with or without compensated cirrhosis				
(Child-Pugh A ONLY)				

Rev. 10/20 Page 2 of 9

☐ Vosevi 400/100/100 mg, one tablet daily plus weight-based ribavirin for 24 weeks



# Request for Prior Authorization HEPATITIS C TREATMENTS

**FAX Completed Form To** 1.877.386.4695

Provider Help Desk 1.866.399.0928

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Re-infection of allograft liver after transplant, treatment naïve or experienced but no direct acting antiviral (DAA)				
experience, no cirrhosis				
<ul> <li>■ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks</li> <li>■ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks</li> </ul>				
Re-infection of allograft liver after transplant, treatment naïve or experienced but no direct acting antiviral (DAA)				
experience, compensated cirrhosis (Child-Pugh A ONLY)				
☐ Mavyret 100/40 mg, three (3) tablet daily for 12 weeks				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
IF multiple negative baseline characteristics, consider				
Mavyret 100/40 mg, three (3) tablets daily plus low dose ribavirin# for 12 weeks				
sofosbuvir/velpatasvir 400/100 mg one tablet daily plus low dose ribavirin# for 12 weeks				
Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis				
☐ Vosevi 400/100/100 mg, one tablet daily for 12 weeks				
Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) compensated cirrhosis (Child-Pugh A ONLY)				
☐ Vosevi 400/100/100 mg, one tablet daily for 12 weeks				
IF multiple negative baseline characteristics, consider				
Vosevi 400/100/100 mg, one tablet daily + low dose ribavirin# for 12 weeks				
Re-infection of allograft liver after transplant, treatment naïve, decompensated cirrhosis (Child-Pugh B or C ONLY)				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus low dose ribavirin# for 12 weeks				
Re-infection of allograft liver after transplant, treatment experienced, decompensated cirrhosis (Child-Pugh B or C ONLY)				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus low dose ribavirin# for 24 weeks				
Decompensated cirrhosis, no prior sofosbuvir or NS5A				
sofosbuvir/velpatasvir 400/100 mg, one tablet plus weight-based ribavirin daily for 12 weeks (low dose ribavirin# if Child-Pugh Class C)				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 24 weeks (will be approved only for patients with documented ineligibility for ribavirin¶)				
Decompensated cirrhosis, prior treatment with sofosbuvir or NS5A				
Decompensated chimosis, phot it earlient with sofospavit of Nosa				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh Class C)				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh Class C)  Genotype 2				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Treatment experienced (PEG-IFN + ribavirin), no cirrhosis				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 8 weeks sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative Mavyret 100/40 mg, three (3) tablets daily for 8 weeks sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), no cirrhosis Mavyret 100/40 mg, three (3) tablets daily for 8 weeks sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks Treatment experienced (PEG-IFN + ribavirin), no cirrhosis Child-Pugh A only)				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 8 weeks sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative Mavyret 100/40 mg, three (3) tablets daily for 8 weeks sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), no cirrhosis Mavyret 100/40 mg, three (3) tablets daily for 8 weeks sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only) Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 8 weeks sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative Mavyret 100/40 mg, three (3) tablets daily for 8 weeks sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Treatment experienced (PEG-IFN + ribavirin), no cirrhosis Mavyret 100/40 mg, three (3) tablets daily for 8 weeks sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only) Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only) Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 8 weeks sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative Mavyret 100/40 mg, three (3) tablets daily for 8 weeks sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Treatment experienced (PEG-IFN + ribavirin), no cirrhosis Mavyret 100/40 mg, three (3) tablets daily for 8 weeks sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only) Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only) Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (Sofosbuvir + ribavirin) with or without compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (sofosbuvir + ribavirin) with or without compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (sofosbuvir + ribavirin) with or without compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (sofosbuvir + ribavirin) with or without compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (sofosbuvir + ribavirin) with or without compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (sofosbuvir + ribavirin) with or without compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
Genotype 2  Treatment naïve, no cirrhosis  ☐ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks ☐ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative ☐ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks ☐ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative ☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive ☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks ☐ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), no cirrhosis ☐ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks ☐ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only) ☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (sofosbuvir + ribavirin), with compensated cirrhosis (Child-Pugh A only) ☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (sofosbuvir + ribavirin) with or without compensated cirrhosis (Child-Pugh A only) ☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks ☐ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks ☐ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks ☐ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks ☐ reatment experienced (direct acting antiviral, including NS5A inhibitors EXCEPT glecaprevir/pibrentasvir (Mavyret) or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures), with or without compensated cirrhosis (Child-Pugh A ONLY)				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily plus weight-based ribavirin daily for 24 weeks (low dose ribavirin#if Child-Pugh Class C)  Genotype 2  Treatment naïve, no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), no cirrhosis □ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks □ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (sofosbuvir + ribavirin) with or without compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (sofosbuvir + ribavirin) with or without compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (sofosbuvir + ribavirin) with or without compensated cirrhosis (Child-Pugh A only) □ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks □ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
Genotype 2  Treatment naïve, no cirrhosis  ☐ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks ☐ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative ☐ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks ☐ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV negative ☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment naïve, compensated cirrhosis (Child-Pugh A ONLY)- HIV positive ☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks ☐ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), no cirrhosis ☐ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks ☐ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks  Treatment experienced (PEG-IFN + ribavirin), with compensated cirrhosis (Child-Pugh A only) ☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (sofosbuvir + ribavirin), with compensated cirrhosis (Child-Pugh A only) ☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Treatment experienced (sofosbuvir + ribavirin) with or without compensated cirrhosis (Child-Pugh A only) ☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks ☐ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks ☐ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks ☐ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks ☐ reatment experienced (direct acting antiviral, including NS5A inhibitors EXCEPT glecaprevir/pibrentasvir (Mavyret) or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures), with or without compensated cirrhosis (Child-Pugh A ONLY)				

Rev. 10/20 Page 3 of 9





Provider Help Desk 1.866.399.0928

## Request for Prior Authorization HEPATITIS C TREATMENTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, compensated cirrhosis (Child-Pugh A only)				
☐ Vosevi 400/100/100 mg, one tablet plus weight-based ribavirin daily for 12 weeks				
Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, with or without compensated cirrhosis				
(Child-Pugh A ONLY)				
Vosevi 400/100/100 mg, one tablet plus weight-based ribavirin daily for 24 weeks				
Decompensated cirrhosis, no prior sofosbuvir or NS5A failure				
□ sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks				
sofosbuvir/velpatasvir 400/100 mg daily for 24 weeks (will be approved only for patients with documented ineligibility for				
ribavirin¶)				
Decompensated cirrhosis, prior sofosbuvir or NS5A failure				
□ sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh C)				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA), no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
Recurrent HCV infection post-liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA)				
experience, compensated cirrhosis (Child-Pugh A ONLY)				
□ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
IF multiple negative baseline characteristics, consider				
☐ Mavyret 100/40, three (3) tablets plus low dose <sup>#</sup> ribavirin daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg plus low dose ribavirin <sup>#</sup> daily for 12 weeks				
Recurrent HCV infection of allograft liver after transplantation, prior treatment with direct acting antivirals (DAA), no				
cirrhosis				
Vosevi 400/100/100 mg, one tablet daily for 12 weeks				
Recurrent HCV infection of allograft liver after transplantation, prior treatment with direct acting antivirals (DAA), compensated cirrhosis (Child-Pugh A ONLY)				
Vosevi 400/100/100 mg, one tablet daily for 12 weeks				
IF multiple negative baseline characteristics, consider				
☐ Vosevi 400/100/100 mg, one tablet daily plus low dose <sup>#</sup> ribavirin for 12 weeks				
Recurrent HCV infection post–liver transplantation, treatment naïve, decompensated cirrhosis (Child-Pugh B and C				
ONLY)				
sofosbuvir/velpatasvir 400/100 mg plus low dose# ribavirin daily for 12 weeks				
Recurrent HCV infection post-liver transplantation, treatment experienced, decompensated cirrhosis (Child-Pugh B				
and C ONLY)				
□ sofosbuvir/velpatasvir 400/100 mg plus low dose <sup>#</sup> ribavirin daily for 24 weeks				
Genotype 3				
Treatment naive, no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
Treatment naïve, with compensated cirrhosis (Child-Pugh A ONLY), HIV negative only				
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks (only if Y93H negative, add weight based ribavirin if				
Y93H positive) Treatment naive, with compensated cirrhosis (Child-Pugh A only), HIV positive				
<u> </u>				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks (Child-Pugh A only)				
sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks (ONLY if Y93H negative)				
Treatment naive, with compensated cirrhosis (Child-Pugh A only), HIV positive only, Y93H positive				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks				

Rev. 10/20 Page 4 of 9





**Provider Help Desk** 1.866.399.0928

# Request for Prior Authorization HEPATITIS C TREATMENTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Treatment experienced (PEG-IFN + ribavirin), no cirrhosis, Y93H positive				
□ sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks				
☐ Mavyret 100/40 mg, three (3) tablets daily for 16 weeks				
☐ Vosevi 400/100/100 mg, one tablet daily for 12 weeks				
Treatment experienced (PEG-IFN + ribavirin), compensated cirrhosis (Child-Pugh A ONLY)				
☐ Mavyret 100/40 mg, three (3) tablets daily for 16 weeks				
sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks				
Treatment experienced (sofosbuvir plus ribavirin +/- PEG-IFN), no or compensated cirrhosis (Child-Pugh A ONLY)				
☐ Mavyret 100/40 mg, three (3) tablets daily for 16 weeks				
Treatment experienced (direct acting antiviral, including NS5A inhibitors EXCEPT glecaprevir/pibrentasvir (Mavyret) or				
sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures), with or without compensated cirrhosis (Child-Pugh A ONLY)				
Vosevi - one tablet daily for 12 weeks (add weight-based ribavirin if both prior NS5A failure and cirrhosis)				
Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, no cirrhosis				
☐ Vosevi - one tablet daily for 12 weeks				
Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, compensated cirrhosis (Child-Pugh A only)				
Vosevi - one tablet daily plus weight-based ribavirin for 12 weeks				
Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, with or without compensated cirrhosis				
(Child-Pugh A ONLY)				
☐ Vosevi - one tablet daily plus weight-based ribavirin for 24 weeks				
Decompensated cirrhosis, no prior sofosbuvir or NS5A failure				
sofosbuvir/velpatasvir 400/100 mg one tablet plus weight-based ribavirin (low dose ribavirin# if Child-Pugh C) daily for				
12 weeks				
sofosbuvir/velpatasvir 400/100 mg daily for 24 weeks (will only be approved for patients with documented ineligibility for ribavirin¶)				
Decompensated cirrhosis, prior sofosbuvir or NS5A failure				
sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh C)				
Recurrent HCV infection post-liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA)				
Recurrent HCV infection post-liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis				
Recurrent HCV infection post-liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
Recurrent HCV infection post-liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA)				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY) sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY) sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Mavyret 100/40 mg, three (3) tablets daily for 12 weeks IF multiple negative baseline characteristics, consider				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY) sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Mavyret 100/40 mg, three (3) tablets daily for 12 weeks IF multiple negative baseline characteristics, consider Mavyret – three (3) tablets daily plus low dose ribavirin# for 12 weeks				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY) sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Mavyret 100/40 mg, three (3) tablets daily for 12 weeks IF multiple negative baseline characteristics, consider Mavyret – three (3) tablets daily plus low dose ribavirin* for 12 weeks sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin* for 12 weeks				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY) sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Mavyret 100/40 mg, three (3) tablets daily for 12 weeks IF multiple negative baseline characteristics, consider Mavyret – three (3) tablets daily plus low dose ribavirin# for 12 weeks sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin# for 12 weeks Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis				
Recurrent HCV infection post-liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Recurrent HCV infection post-liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY) sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Mavyret 100/40 mg, three (3) tablets daily for 12 weeks IF multiple negative baseline characteristics, consider Mavyret – three (3) tablets daily plus low dose ribavirin# for 12 weeks sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin# for 12 weeks Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis Vosevi - one tablet daily for 12 weeks				
Recurrent HCV infection post-liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Recurrent HCV infection post-liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY) sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Mavyret 100/40 mg, three (3) tablets daily for 12 weeks IF multiple negative baseline characteristics, consider Mavyret – three (3) tablets daily plus low dose ribavirin# for 12 weeks sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin# for 12 weeks Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis Vosevi - one tablet daily for 12 weeks Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) compensated cirrhosis				
Recurrent HCV infection post-liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Recurrent HCV infection post-liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY) sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Mavyret 100/40 mg, three (3) tablets daily for 12 weeks IF multiple negative baseline characteristics, consider Mavyret – three (3) tablets daily plus low dose ribavirin# for 12 weeks sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin# for 12 weeks Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis Vosevi - one tablet daily for 12 weeks				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis    Mavyret 100/40 mg, three (3) tablets daily for 12 weeks   sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks   Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY)   sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks   Mavyret 100/40 mg, three (3) tablets daily for 12 weeks   IF multiple negative baseline characteristics, consider   Mavyret – three (3) tablets daily plus low dose ribavirin# for 12 weeks   sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin# for 12 weeks   Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis   Vosevi - one tablet daily for 12 weeks   Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) compensated cirrhosis (Child-Pugh A ONLY)   Vosevi - one tablet daily for 12 weeks   IF multiple negative baseline characteristics, consider				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis    Mavyret 100/40 mg, three (3) tablets daily for 12 weeks   sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks   Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY)   sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks   Mavyret 100/40 mg, three (3) tablets daily for 12 weeks   Mavyret - three (3) tablets daily plus low dose ribavirin# for 12 weeks   Mavyret - three (3) tablets daily plus low dose ribavirin# for 12 weeks   sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin# for 12 weeks   vosevi - one tablet daily for 12 weeks   Vosevi - one tablet daily for 12 weeks   Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) compensated cirrhosis (Child-Pugh A ONLY)   Vosevi - one tablet daily for 12 weeks   Fmultiple negative baseline characteristics, consider   Vosevi - one tablet daily + low dose ribavirin# for 12 weeks   Vosevi - one tablet daily + low dose ribavirin# for 12 weeks				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis    Mavyret 100/40 mg, three (3) tablets daily for 12 weeks   sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks   Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY)   sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks   Mavyret 100/40 mg, three (3) tablets daily for 12 weeks   Mavyret - three (3) tablets daily plus low dose ribavirin# for 12 weeks   sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin# for 12 weeks   Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis   Vosevi - one tablet daily for 12 weeks   Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) compensated cirrhosis (Child-Pugh A ONLY)   Vosevi - one tablet daily for 12 weeks   IF multiple negative baseline characteristics, consider   Vosevi - one tablet daily + low dose ribavirin# for 12 weeks   Recurrent HCV infection post–liver transplantation, treatment naïve, decompensated cirrhosis (Child-Pugh B and C				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis    Mavyret 100/40 mg, three (3) tablets daily for 12 weeks   sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks   Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY)   sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks   Mavyret 100/40 mg, three (3) tablets daily for 12 weeks   Mavyret - three (3) tablets daily plus low dose ribavirin# for 12 weeks   Mavyret - three (3) tablets daily plus low dose ribavirin# for 12 weeks   Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis   Vosevi - one tablet daily for 12 weeks   Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) compensated cirrhosis (Child-Pugh A ONLY)   Vosevi - one tablet daily for 12 weeks   Fmultiple negative baseline characteristics, consider   Vosevi - one tablet daily + low dose ribavirin# for 12 weeks   Recurrent HCV infection post-liver transplantation, treatment naïve, decompensated cirrhosis (Child-Pugh B and CONLY)				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis    Mavyret 100/40 mg, three (3) tablets daily for 12 weeks   sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks   Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY)   sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks   Mavyret 100/40 mg, three (3) tablets daily for 12 weeks   Mavyret - three (3) tablets daily plus low dose ribavirin# for 12 weeks   sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin# for 12 weeks   Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis   Vosevi - one tablet daily for 12 weeks   Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) compensated cirrhosis (Child-Pugh A ONLY)   Vosevi - one tablet daily for 12 weeks   IF multiple negative baseline characteristics, consider   Vosevi - one tablet daily + low dose ribavirin# for 12 weeks   Recurrent HCV infection post–liver transplantation, treatment naïve, decompensated cirrhosis (Child-Pugh B and C				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY)  sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks  Hmultiple negative baseline characteristics, consider  Mavyret – three (3) tablets daily plus low dose ribavirin* for 12 weeks  sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin* for 12 weeks  Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis  vosevi - one tablet daily for 12 weeks  Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) compensated cirrhosis (Child-Pugh A ONLY)  vosevi - one tablet daily for 12 weeks  IF multiple negative baseline characteristics, consider  vosevi - one tablet daily + low dose ribavirin* for 12 weeks  Recurrent HCV infection post–liver transplantation, treatment naïve, decompensated cirrhosis (Child-Pugh B and C ONLY)  sofosbuvir/velpatasvir - one tablet daily plus low-dose ribavirin* for 12 weeks  Recurrent HCV infection post–liver transplantation, treatment experienced, decompensated cirrhosis (Child-Pugh B and C ONLY)				
Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA) experience, no cirrhosis  Mavyret 100/40 mg, three (3) tablets daily for 12 weeks sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks  Recurrent HCV infection post–liver transplantation, treatment naïve or experienced, but no direct acting antiviral (DAA) experience, compensated cirrhosis (Child-Pugh A ONLY) sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks Mavyret 100/40 mg, three (3) tablets daily for 12 weeks IF multiple negative baseline characteristics, consider Mavyret – three (3) tablets daily plus low dose ribavirin# for 12 weeks sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin# for 12 weeks Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis Vosevi - one tablet daily for 12 weeks Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) compensated cirrhosis (Child-Pugh A ONLY) Vosevi - one tablet daily for 12 weeks IF multiple negative baseline characteristics, consider Vosevi - one tablet daily + low dose ribavirin# for 12 weeks Recurrent HCV infection post–liver transplantation, treatment naïve, decompensated cirrhosis (Child-Pugh B and C ONLY) sofosbuvir/velpatasvir - one tablet daily plus low-dose ribavirin# for 12 weeks Recurrent HCV infection post–liver transplantation, treatment experienced, decompensated cirrhosis (Child-Pugh B				

Rev. 10/20 Page 5 of 9



### Request for Prior Authorization HEPATITIS C TREATMENTS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

**FAX Completed Form To** 1.877.386.4695

Provider Help Desk 1.866.399.0928

Genotype 4				
Treatment naïve, no cirrhosis				
☐ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
Treatment naïve, compensated cirrhosis (Child-Pugh A only), HIV negative				
■ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
Treatment naïve, compensated cirrhosis (Child-Pugh A only), HIV positive				
☐ Mavyret - three (3) tablets daily for 12 weeks				
sofosbuvir/velpatasvir – one tablet daily for 12 weeks				
Treatment experienced (PEG-IFN/RBV ONLY), no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
Treatment experienced (PEG-IFN/RBV ONLY), compensated cirrhosis (Child-Pugh A only)				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
Treatment experienced (any direct acting antiviral including NS5A inhibitors), EXCEPT glecaprevir/pibrentasvir				
(Mavyret) or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures) with or without compensated cirrhosis (Child-Pugh A				
ONLY)				
☐ Vosevi 400/100/100 mg daily for 12 weeks  Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, no cirrhosis				
☐ Vosevi - one tablet daily for 12 weeks				
Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, compensated cirrhosis (Child-Pugh A only)				
☐ Vosevi - one tablet daily plus weight-based ribavirin for 12 weeks				
Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, with or without compensated cirrhosis				
(Child-Pugh A ONLY)				
☐ Vosevi - one tablet daily + weight-based ribavirin for 24 weeks				
Decompensated cirrhosis, no prior sofosbuvir or NS5A				
□ sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks (low dose ribavirin# if Child-Pugh C)				
sofosbuvir/velpatasvir 400/100 mg daily for 24 weeks (will only be approved for patients with documented ineligibility for				
ribavirin¶)				
Decompensated cirrhosis, prior sofosbuvir or NS5A failure				
sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh C)  Recurrent HCV infection post–liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA)				
experience, no cirrhosis				
☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
Re-infection of allograft liver after transplant, treatment naïve or experienced but no direct acting antiviral (DAA)				
experience, compensated cirrhosis (Child-Pugh A ONLY)				
☐ Mavyret – three (3) tablets daily for 12 weeks				
□ sofosbuvir/velpatasvir one tablet daily for 12 weeks				
IF multiple negative baseline characteristics, consider				
Mavyret – three (3) tablets daily plus low dose ribavirin <sup>#</sup> for 12 weeks				
sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin# for 12 weeks				
Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis				
□ Vosevi - one tablet daily for 12 weeks  Po infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) compensated circhesis				
Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) compensated cirrhosis (Child-Pugh A ONLY)				
Vosevi - one tablet daily for 12 weeks				
IF multiple negative baseline characteristics, consider				
☐ Vosevi - one tablet daily + low dose ribavirin# for 12 weeks				
Recurrent HCV infection post-liver transplantation, treatment naïve, decompensated cirrhosis (Child-Pugh B and C				
ONL <u>Y</u> )				
Sofosbuvir/velpatasvir - one tablet daily plus low-dose ribavirin for 12 weeks				

470-5270 (Rev. 10/20) Page 6 of 9





Provider Help Desk 1.866.399.0928

### Request for Prior Authorization HEPATITIS C TREATMENTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Recurrent HCV infection post–liver transplantation, treatment experienced, decompensated cirrhosis (Child-Pugh B and C ONLY)				
sofosbuvir/velpatasvir - one tablet daily plus low-dose ribavirin# for 24 weeks				
Genotype 5 or 6				
Treatment naïve, with or without compensated cirrhosis (Child-Pugh A ONLY), HIV negative ONLY  Mayyret 100/40 mg, three (3) tablets daily for 8 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
Treatment naïve, with or without compensated cirrhosis (Child-Pugh A ONLY), HIV positive ONLY				
☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
Treatment experienced (PEG-IFN/RBV), no cirrhosis				
☐ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks				
□ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks				
Treatment experienced (PEG-IFN/RBV), compensated cirrhosis (Child-Pugh A ONLY)				
☐ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
□ sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
Treatment experienced (any Direct Acting HCV Antiviral (DAA) including NS5A inhibitors, EXCEPT				
glecaprevir/pibrentasvir (Mavyret) or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures) with no or compensated				
cirrhosis (Child-Pugh A ONLY)				
Vosevi 400/100/100 mg daily for 12 weeks				
Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, no cirrhosis				
Vosevi - one tablet daily for 12 weeks  Treatment experienced, glecaprevir/pibrentasvir (Mavyret) failures, compensated cirrhosis (Child-Pugh A only)				
☐ Vosevi - one tablet daily plus weight-based ribavirin for 12 weeks				
Treatment experienced, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) failures, with or without compensated cirrhosis				
(Child-Pugh A ONLY)				
☐ Vosevi - one tablet daily + weight-based ribavirin for 24 weeks				
Decompensated cirrhosis, no prior sofosbuvir or NS5A				
sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 12 weeks (low dose ribavirin# if Child-Pugh C)				
sofosbuvir/velpatasvir 400/100 mg daily for 24 weeks (will only be approved for patients with documented ineligibility to				
ribavirin¶)				
Decompensated cirrhosis, prior treatment with sofosbuvir or NS5A				
sofosbuvir/velpatasvir 400/100 mg plus weight-based ribavirin daily for 24 weeks (low dose ribavirin# if Child-Pugh C)				
Recurrent HCV infection post-liver transplantation, treatment naïve or experienced but no direct acting antiviral (DAA)				
experience, no cirrhosis				
Mavyret 100/40 mg, three (3) tablets daily for 12 weeks				
sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks				
Re-infection of allograft liver after transplant, treatment naïve or experienced but no direct acting antiviral (DAA)				
experience, compensated cirrhosis (Child-Pugh A ONLY)				
Mavyret – three (3) tablets daily for 12 weeks				
□ sofosbuvir/velpatasvir one tablet daily for 12 weeks IF multiple negative baseline characteristics, consider				
Mavyret – three (3) tablets daily plus low dose ribavirin <sup>#</sup> for 12 weeks				
sofosbuvir/velpatasvir one tablet daily plus low dose ribavirin <sup>#</sup> for 12 weeks  Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) no cirrhosis				
☐ Vosevi - one tablet daily for 12 weeks  Re-infection of allograft liver after transplant, prior treatment with direct acting antivirals (DAA) compensated cirrhosis				
(Child-Pugh A ONLY)				
☐ Vosevi - one tablet daily for 12 weeks				
IF multiple negative baseline characteristics, consider				
☐ Vosevi - one tablet daily + low dose ribavirin# for 12 weeks				
Recurrent HCV infection post–liver transplantation, treatment naïve, decompensated cirrhosis (Child-Pugh B and C				
ONLY)				
□ sofosbuvir/velpatasvir - one tablet daily plus low-dose ribavirin# for 12 weeks				

Rev. 10/20 Page 7 of 9

#### **Request for Prior Authorization HEPATITIS C TREATMENTS**

1.877.386.4695

**FAX Completed Form To** 

**Provider Help Desk** 

(PLEASE PRINT - ACCURACY IS IMPORTANT) 1.866.399.0928 Recurrent HCV infection post-liver transplantation, treatment experienced, decompensated cirrhosis (Child-Pugh B

	d C ONLY)  sofosbuvir/velpatasvir - one tablet daily plus low-dose ribavirin <sup>#</sup> for 24 weeks			
Oth	ner Treatment Regimen			
Genotype, treatment history, and extent of liver disease:				
Drug names, doses and durations:				
Clir	nical rationale for selecting regimens other than those outlined above:			
Ab	breviations: PEG-IFN=peg-interferon; RBV=ribavirin; PI=protease inhibitor; DAA=direct acting antiviral			
# lo	ow dose ribavirin = 600 mg/day and increase as tolerated			
SE	ECTION 2 – SUPPORTING DOCUMENTATION			
Re	view and complete each numbered item below to provide the supporting documentation for the PA request.			
Dia	gnosis:			
1.	Pretreatment viral load (attach results): Date Obtained:			
Pat	tient History:			
2.	Does the patient have a history of non-compliance?  Yes  No If yes, submit chart notes documenting the steps taken to correct or address the non-compliance (attach chart notes)			
3.	3. Documentation in provider notes (must be submitted) showing that member has had no abuse of alcohol and drugs for the previous 3 months. MUST submit urine drug screen for members with history of abuse of drugs other than alcohol. Counseling MUST be provided and documented regarding non-abuse of alcohol and drugs as well as education on how to prevent HCV transmission			
4.	4. Has patient been screened for Hepatitis B? No Yes Date: Active Disease: No Yes If yes, has patient been treated or currently being treated? No Yes			
5.	Patient weight: Date obtained:			
6.	Does patient have a limited life expectancy (less than 12 months) due to non-liver-related comorbid conditions?			
Pre	escriber Information:			
7.	Provider Practice: Digestive Disease Liver Disease Infectious Disease Other:			
	If other, note consultation with Specialist:			
	Consultation Date: Physician Name, Phone & Specialty:			
Reg	gimens Containing Ribavirin:			
8.	If the patient is female and of childbearing potential, or the patient is male with a female partner of childbearing potential, the prescriber must acknowledge the following:			
	<ul> <li>The patient is not pregnant (or a male patient with a pregnant female partner) and is not planning to become pregnant during treatment or within 6 months of stopping treatment.</li> <li>Both partners will use two forms of effective contraception during treatment and for at least 6 months after stopping treatment.</li> <li>Monthly pregnancy tests will be performed throughout treatment.</li> </ul>			
9.	Complete blood count with differential (attach results)			
10.	If the patient is ineligible for ribavirin¶, select the appropriate reason from the list below:			
	<ul> <li>□ History of severe or unstable cardiac disease</li> <li>□ Pregnant women and men with pregnant partners</li> <li>□ Diagnosis of hemoglobinopathy (e.g., thalassemia major, sickle cell anemia)</li> <li>□ Hypersensitivity to ribavirin</li> <li>□ Baseline platelets &lt;70,000 cells/μL</li> <li>□ Baseline absolute neutrophil count &lt;1,500 cells/μL</li> </ul>			

Page 8 of 9 Rev. 10/20





**Provider Help Desk** 1.866.399.0928

## Request for Prior Authorization HEPATITIS C TREATMENTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Baseline hemoglobin <12 g/dL in women or <13 g/dL in men Other:  Note: Laboratory values will be reviewed and requests will not be considered if labs are outside of a specific range. Patients with CrCl <50 ml/min (moderate or severe renal dysfunction, ESRD, HD) should have dosage reduced.					
11. By checking the following box, the prescriber attests that they have reviewed the patient's medications for potentially significant drug interactions with the Hepatitis C treatment on an electronic drug interaction website.					
☐ Website used:	Date completed:				
Attach lab results and other documentation					
Prescriber signature (Must match prescriber listed above.)	Date of submission				

**IMPORTANT NOTE:** In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

Rev. 10/20 Page 9 of 9